🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Xinjiang Medical University clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Xinjiang Medical University as lead sponsor. Synced 26 Sep 2026
8Current trials
6Recruiting now
0Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Xinjiang Medical University is the lead sponsor of 8 current clinical trials in our China register. 6 are recruiting patients now. The most common phase is Observational. The most-studied condition is Primary Aldosteronism.

ClinicalTrials.gov trials by status

  • Recruiting675%
  • Not yet open225%

Trials by phase

  • Observational675%
  • Not applicable225%
01

Clinical trials sponsored by Xinjiang Medical University

8 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Prognostic Model of Hypertension
NCT06160921 · ClinicalTrials.gov ↗ · Hypertension
Observational Recruiting 2020-01 China
Primary Aldosteronism: Superselective Embolization vs. Laparoscopic Endocrine Curative Therapy
NCT06513585 · ClinicalTrials.gov ↗ · Primary Aldosteronism, Suprarenalectomy, Super Selective Adrenal Artery Embolization
Not applicable Recruiting 2024-08 China
The Association Between Primary Aldosteronism and Cognitive Dysfunction
NCT07304674 · ClinicalTrials.gov ↗ · Primary Aldosteronism, Cognitive Dysfunction, Mild Cognitive Impairment (MCI)
Observational Recruiting 2025-12 China
Prognosis of Primary Aldosteronism: A Prospective Cohort Study
NCT07378176 · ClinicalTrials.gov ↗ · Primary Aldosteronism
Observational Recruiting 2026-01 China
Clinical Outcomes of Cardiovascular Disease
NCT06459934 · ClinicalTrials.gov ↗ · Cardiovascular Diseases, Heart Failure, Coronary Artery Disease
Observational Recruiting 2024-06 China
Super Selective Adrenal Artery Embolization for Primary Aldosteronism: a Prospective Cohort Study(SAAE-PA)
NCT06513676 · ClinicalTrials.gov ↗ · Primary Aldosteronism, Super Selective Adrenal Arterial Embolization
Observational Recruiting 2024-04 China
Precision Subtyping and Prognostic Study of Heart Failure Based on Multi-Omics Integration and Clinical Indicators: A Prospective Single-Center Cohort Study
NCT07355088 · ClinicalTrials.gov ↗ · Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF)
Observational Not yet open 2026-01 China
Structured Cardio-Oncology Rehabilitation for Cardiovascular Outcomes in Cancer Survivors
NCT07622394 · ClinicalTrials.gov ↗ · Cancer Therapy-Related Cardiac Dysfunction, Cardio-oncology, Cancer Survivorship
Not applicable Not yet open 2026-09 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in Xinjiang Medical University trials

19 conditions
Primary Aldosteronism4Hypertension1Chronic Heart Failure1Heart Failure With Reduced Ejection Fraction (HFrEF)1Heart Failure With Preserved Ejection Fraction (HFPEF)1Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)1Suprarenalectomy1Super Selective Adrenal Artery Embolization1Cancer Therapy-Related Cardiac Dysfunction1Cardio-oncology1Cancer Survivorship1Cardiovascular Risk1Cognitive Dysfunction1Mild Cognitive Impairment (MCI)1Dementia1Cardiovascular Diseases1Heart Failure1Coronary Artery Disease1Super Selective Adrenal Arterial Embolization1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in China86

A trial with sites in more than one country appears in each of those registers.

04

Other sponsors in Primary Aldosteronism

SponsorTrials
Qifu Li5
Chongqing Medical University3
Third Military Medical University2

Sponsors with the most current trials registered for this condition.

05

Questions about Xinjiang Medical University trials

How many clinical trials does Xinjiang Medical University sponsor?

Xinjiang Medical University is the lead sponsor of 8 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Xinjiang Medical University trials recruiting?

Yes. 6 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.